AMANTA vs BALAXI: Stock Comparison
AMANTA is the larger company by market capitalisation. AMANTA shows a higher ROE, faster revenue growth and a higher ROCE, while BALAXI PHARMA shows a lower P/E and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AMANTA leads 9; BALAXI leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AMANTA | BALAXI |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AMANTA | BALAXI |
|---|---|---|
| Live Price | ₹150.27 | ₹23.45 |
| Day Change | -4.37% | 0.51% |
| Volume | 3.82 L | 5,566 |
| 52-Week High | ₹164 | ₹47.71 |
| 52-Week Low | ₹92 | ₹15.2 |
| Distance from 52W High | -8.37% | -50.85% |
Valuation
| Metric | AMANTA | BALAXI |
|---|---|---|
| Market Cap | ₹749 Cr | ₹129 Cr |
| P/E Ratio | 53.58x | 12.63x |
| P/B Ratio | 3.57x | 0x |
| EPS | ₹0.85 | ₹0.45 |
| Book Value | ₹56.71 | ₹45.12 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | AMANTA | BALAXI |
|---|---|---|
| Revenue Growth (TTM YoY) | 6.8% | -25.76% |
| EPS Growth (TTM YoY) | -23.4% | -58.44% |
| Qtr Sales Growth | -76.08% | -80.68% |
| Qtr Profit Growth | -77.74% | -196.59% |
Profitability & Leverage
| Metric | AMANTA | BALAXI |
|---|---|---|
| ROE | 6.75% | 3.87% |
| ROCE | 7.89% | 4.42% |
| Net Margin | 5.17% | 0.52% |
| Operating Margin | 14.55% | 12.03% |
| Debt to Equity | 1.06x | 0.25x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AMANTA | BALAXI |
|---|---|---|
| Promoter Holding | 26.87%▲ 0.06 pp | 65.99% |
| FII Holding | 0.43%▼ 0.42 pp | 0% |
| DII Holding | 12.92%▲ 0.04 pp | 2.56% |
| Public Holding | 22.85%▲ 0.29 pp | 31.45% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AMANTA and BALAXI PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.